Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Madame Bioscience PCLBKK:MADAME -4.95%34 Piotroski F-Score is 7 as of Sep. 04, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates BKK:MADAME with a GF Score™ of 34/100 and a GF Value™ of ฿0.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,929 Consumer Packaged Goods companies, Madame Bioscience PCL ranks better than 89.32% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Madame Bioscience PCL has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Madame Bioscience PCL's Piotroski F-Score or its related term are showing as below:
BKK:MADAME'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 7
Current: 7
During the past 13 years, the highest Piotroski F-Score of Madame Bioscience PCL was 7. The lowest was 2. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Madame Bioscience PCL Piotroski F-Score Related Terms
Madame Bioscience PCL Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Madame Bioscience PCL's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:MADAME vs KHC, GIS: Piotroski F-Score Comparison
For the Packaged Foods subindustry, Madame Bioscience PCL's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madame Bioscience PCL Piotroski F-Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Madame Bioscience PCL's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Madame Bioscience PCL's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Madame Bioscience PCL's current Net Income (TTM) was -141.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Madame Bioscience PCL's return on assets of this year was -0.09140101. Madame Bioscience PCL's return on assets of last year was -0.04356202.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Madame Bioscience PCL's gearing of this year was 0.10507129. Madame Bioscience PCL's gearing of last year was 0.13976379.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Madame Bioscience PCL's current ratio of this year was 1.51473699. Madame Bioscience PCL's current ratio of last year was 0.9169145.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Madame Bioscience PCL's number of shares in issue this year was 806.133. Madame Bioscience PCL's number of shares in issue last year was 807.809.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Madame Bioscience PCL's gross margin of this year was 0.28415279. Madame Bioscience PCL's gross margin of last year was 0.16851949.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Madame Bioscience PCL's asset turnover of this year was 1.02589353. Madame Bioscience PCL's asset turnover of last year was 0.88887228.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
0
+
1
+
1
+
1
+
1
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Madame Bioscience PCL has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Madame Bioscience PCL (BKK:MADAME) has a Piotroski F-Score of 7 as of Sep. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Madame Bioscience PCL and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Madame Bioscience PCL's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Madame Bioscience PCL ranks #206 out of 1929 companies in the Consumer Packaged Goods industry, placing it in the top 10.7%.
Is Madame Bioscience PCL's Piotroski F-Score too high?
Madame Bioscience PCL's current Piotroski F-Score of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Consumer Packaged Goods industry median Piotroski F-Score is 5.00. Madame Bioscience PCL's value of 7 is 40% above this industry median. Based on the distribution chart, Madame Bioscience PCL ranks #206 out of 1929 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Madame Bioscience PCL has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Madame Bioscience PCL's Piotroski F-Score compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Madame Bioscience PCL ranks #206 out of 1929 companies for Piotroski F-Score. This places Madame Bioscience PCL in the top 11% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Madame Bioscience PCL's value of 7 is 40% above this benchmark. Historically, Madame Bioscience PCL's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Madame Bioscience PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Consumer Packaged Goods company?
The median Piotroski F-Score among Consumer Packaged Goods companies is 5.00, based on 1,929 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Madame Bioscience PCL's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Madame Bioscience PCL and its competitors. For the Consumer Packaged Goods industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Madame Bioscience PCL's current Piotroski F-Score is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madame Bioscience PCL stock overvalued right now?
Based on GuruFocus' analysis, Madame Bioscience PCL (BKK:MADAME) is currently considered Significantly Overvalued. The stock's GF Value™ is ฿0.62, compared to a current price of ฿0.96 — trading 54.8% above its estimated fair value. The current Piotroski F-Score is 7, which is 75% above median its 10-year median of 4.00 and 40% above the Consumer Packaged Goods industry median of 5.00. Madame Bioscience PCL's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Madame Bioscience PCL (BKK:MADAME), the current Piotroski F-Score is 7 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Madame Bioscience PCL (BKK:MADAME) Overvalued in 2026?
Based on GuruFocus' analysis, Madame Bioscience PCL stock appears to be overvalued.
The current stock price of ฿0.96 is trading 54.8% above its estimated GF Value™ of ฿0.62.
GuruFocus considers Madame Bioscience PCL to be Significantly Overvalued.
Key valuation signals for BKK:MADAME:
Piotroski F-Score: 7 (75% above median its 10-year median of 4.00)
GF Value™: ฿0.62 vs. price of ฿0.96 (54.8% above fair value)
Industry Position: 40% above the Consumer Packaged Goods median (#206 of 1929)
No single metric tells the full story. See the BKK:MADAME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Madame Bioscience PCL is engaged in the segments of the Packaging business, Food business, Retail sales of cosmetics, and Other businesses. Its activities include the manufacturing and selling of plastic packaging, restaurant business, advertising rental service in the gas station and manufacturing and selling of dried fruits, among others. The group derives a majority of its revenue from the Food business. The firm's product portfolio includes Ready meals, Frozen food, value-added seafood and vegetables, Flexible packaging, and PET Bottles.
34GF Score
Get the complete analysis for BKK:MADAME
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:MADAME has been successfully added to your 
